Home | HealthCare Royalty Partners

Advancing Biopharmaceutical Innovation with Creative Capital Solutions

HealthCare Royalty is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products.

Royalty Monetization

Corporate Financing

$5B+

Invested in more than 85 biopharma products since inception

NY

New York Metro Area

CA

San Francisco

MA

Boston

UK

London

34

Team Members

Meet Our Team

Team

Interview with Dr. Robert Langer, HCRx Senior Advisor

Interview with Gary Lyons, HCRx Senior Advisor

Interview with Dr. Greg Went, Former Chairman & CEO, Adamas Pharmaceuticals (December 2017)

Interview with Julie McHugh, HCRx Senior Advisor

Interview with Julie Anne Smith, Former President and CEO, Raptor Pharmaceuticals

Interview with Nat Ricciardi, HCRx Senior Advisor

Spotlight

Latest News

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Zevra Therapeutics Refinances Existing Debt With Up To $100M In Committed Capital Under New Credit Facility

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

Liquidia Corporation Announces $100 Million in New Financings

HealthCare Royalty Announces Closing of Additional Debt Focused Fund, Team Expansion, and Promotions